Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc. (NASDAQ: MGX) is a biotechnology company dedicated to the discovery and development of novel gene editing tools derived from metagenomic data. Leveraging proprietary artificial intelligence and bioinformatic platforms, the company searches through vast environmental DNA datasets to identify and characterize unique CRISPR-associated (Cas) enzymes. Metagenomi’s approach aims to expand the toolbox of gene editing by uncovering enzymes with enhanced specificity, reduced off-target activity and novel editing capabilities beyond those offered by existing CRISPR systems.

The company’s core business activities include the licensing of newly discovered Cas enzymes to pharmaceutical and biotechnology partners, as well as the in-house development of advanced gene editing solutions for therapeutic and agricultural applications. Metagenomi collaborates with leading industry players to co-develop targeted therapies for genetic disorders and to engineer crop traits that enhance yield, disease resistance and environmental resilience. Its technology platform is designed to streamline the enzyme discovery process and accelerate the translation of research into commercial products.

Headquartered in Berkeley, California, Metagenomi maintains research collaborations and partnerships across North America, Europe and Asia. The company operates a state-of-the-art laboratory facility where multidisciplinary teams of molecular biologists, computational scientists and protein engineers work to validate and optimize novel gene editing tools. Metagenomi’s global network enables it to tailor solutions to diverse markets, from human health to sustainable agriculture, while ensuring compliance with evolving regulatory standards.

Founded in 2018, Metagenomi is led by CEO Haley Warfel, who brings experience in genetic engineering and strategic alliances, alongside a seasoned executive team with backgrounds in genomics, drug development and business development. Since its inception, the company has advanced multiple Cas enzyme candidates through preclinical validation and established strategic collaborations that underscore its position at the forefront of next-generation gene editing innovation.

Key Stats

• Today's Range: $2.04 to $2.22
• 50-Day Range: $1.42 to $2.33
• 52-Week Range: $1.23 to $5.50
• Volume: 726,050 shs
• Average Volume: 868,342 shs
• Market Capitalization: $81.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 57% of companies evaluated by MarketBeat, and ranked 580th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Metagenomi has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Metagenomi has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Metagenomi has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.79% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently decreased by 29.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.79% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently decreased by 29.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.94

News Sentiment

Metagenomi has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Metagenomi this week, compared to 6 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,800.00 in company stock.

Percentage Held by Insiders

17.80% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

MGX Stock Analysis - Frequently Asked Questions

How have MGX shares performed this year?

Metagenomi's stock was trading at $3.61 on January 1st, 2025. Since then, MGX stock has decreased by 39.6% and is now trading at $2.18.

How were Metagenomi's earnings last quarter?

Metagenomi, Inc. (NASDAQ:MGX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $8.75 million. Metagenomi had a negative trailing twelve-month return on equity of 31.21% and a negative net margin of 172.21%.

When did Metagenomi IPO?

Metagenomi (MGX) raised $94 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

How do I buy shares of Metagenomi?

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Metagenomi own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 236
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Metagenomi: $13.00
• High Price Target: $17.00
• Low Price Target: $7.00
• Potential Upside/Downside: +507.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$78.06 million
• Net Margins: -172.21%
• Pretax Margin: -184.18%
• Return on Equity: -31.21%
• Return on Assets: -22.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.85
• Quick Ratio: 5.85

Sales & Book Value

• Annual Sales: $52.29 million
• Price / Sales: 1.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.28 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 37,380,000
• Free Float: 30,727,000
• Market Cap: $79.96 million
• Optionable: N/A
• Beta: -0.38